Results 21 to 30 of about 58,972 (283)
PLoS Biology, 2019 During rheumatoid arthritis (RA) treatment, long-term injection of antitumor necrosis factor α antibodies (anti-TNFα Abs) may induce on-target toxicities, including severe infections (tuberculosis [TB] or septic arthritis) and malignancy.
Yun-Chi Lu +13 more
doaj +1 more source
Infliximab-Induced Aseptic Meningitis during the Treatment of Psoriatic Arthritis
Case Reports in Dermatology, 2017 A 42-year-old Japanese man presented with persistent headache during treatment for psoriatic arthritis (PsA) with infliximab. Treatment with infliximab was initiated 3 years before and the psoriatic skin lesions with arthritis were well controlled ...
Yuki Matsuura-Otsuki +3 more
doaj +1 more source
Infliximab therapy in refractory sarcoidosis: a multicenter real-world analysis
Respiratory Research, 2022 Background Infliximab is a monoclonal antibody that binds and neutralizes circulating tumor necrosis factor-alpha, a key inflammatory cytokine in the pathophysiology of sarcoidosis.
Abdullah Sakkat +9 more
doaj +1 more source
Inflammatory Intestinal Diseases, 2021 Background: TNF inhibitors are relatively safe drugs, but asymptomatic infliximab-induced high serum creatine kinase (CK) levels have been reported in >30% of patients with inflammatory bowel disease (IBD).
Manuel Sutter +2 more
doaj +1 more source
Therapeutic Advances in Gastroenterology, 2015 Objectives: Many patients with Crohn’s disease on infliximab maintenance therapy have recurrent symptoms despite an initial clinical response. Therefore, concomitant therapies have been studied.
Douglas L. Nguyen +5 more
doaj +1 more source
Loss of Response to Long-Term Infliximab Therapy in Children with Crohn’s Disease
Pharmaceuticals, 2013 Secondary loss of response (LoR) often precludes further use of infliximab in children with Crohn’s disease. Immunomodulators may reduce the incidence of LoR but their combination with infliximab presents safety concerns.
George Alex +3 more
doaj +1 more source
Arthritis Research & Therapy, 2019 Introduction Biosimilar infliximab has the potential for appreciable cost savings compared to its reference biologic, but dose escalation is common and increases costs.
Jeffrey R. Curtis +3 more
doaj +1 more source
Journal of Clinical Rheumatology and Immunology, 2022 Objective: Efficacy, tolerance, and safety of infliximab biosimilar are the same as infliximab reference product (RP) in the management of ankylosing spondylitis (AS) patients previously were on infliximab RP.
Abdulsatar J. Mathkhor +3 more
doaj +1 more source
Early Serum Infliximab Levels in Pediatric Ulcerative Colitis
Frontiers in Pediatrics, 2021 Background: Data on serum infliximab concentrations during induction in pediatric ulcerative colitis are limited. The study aim is to evaluate the relationship between serum infliximab concentrations during induction and short-term clinical remission in ...
Jennifer C. C. deBruyn +10 more
doaj +1 more source
Arthritis Care &Research, EarlyView.Objective Systemic lupus erythematosus (SLE) is a heterogenous inflammatory condition with widely varying global prevalence estimates. The frequency of SLE in the general population of Australia has been reported to be notably lower than contemporary estimates in countries such as the United States or United Kingdom, at 19 to 39 per 100,000 as opposed ...
Lucinda Roper +7 more
wiley +1 more source